AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01249352
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
Trial: NCT02852395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose; appearance matched to JNJ-48816274
Trial: NCT01051635
Drug: LMP400
RxNorm normalized name: LMP400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
Trial: NCT04012099
Drug: BMT101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection to each of 3 dose-groups.
Trial: NCT01020747
Drug: Avastin® (bevacizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab injections (\~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
Trial: NCT03028012
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Trial: NCT01726517
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
Trial: NCT04119050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as intravenous infusion
Trial: NCT01474421
Drug: AQW051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive AQW051 in a high dose once daily orally for 28 days.
Trial: NCT01474421
Drug: AQW051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive AQW051 in a low dose once daily orally for 28 days.
Trial: NCT01474421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo once daily orally for 28 days.
Trial: NCT03990519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive sodium chloride injection as placebo on Day 1.
Trial: NCT02920021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion
Trial: NCT00688077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
Trial: NCT04410354
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg (total daily dose of 0 mg) for 10 days
Trial: NCT02659384
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02659384
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02091297
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia
Trial: NCT01024036
Drug: Best Supportive Care (BSC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
Trial: NCT02865135
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
Trial: NCT00574171
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
Trial: NCT02805595
Drug: 23.4% Hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Injections
Trial: NCT01778647
Drug: Stimulants plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
Trial: NCT00796614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02514577
Drug: IDP-122 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lotion
Trial: NCT02514577
Drug: IDP-122 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lotion. No active ingredient.
Trial: NCT02675998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00043186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection
Trial: NCT00369603
Drug: Razadyne ER
RxNorm normalized name: Razadyne ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
Trial: NCT00199160
Drug: BAY 43-9006
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02750553
Drug: SHR0534
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02750553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182583
Drug: Ba253MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182583
Drug: Ba253BINEB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00944996
Drug: SSRI; SNRI; TCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets or Pills, 1 or 2 per day, more than 2 month
Trial: NCT00157690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg 1 x weekly for 12 months
Trial: NCT02428218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enteric-coated microtablets
Trial: NCT00725036
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00725036
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02413099
Drug: KBMSI-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
Trial: NCT01916798
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
Trial: NCT04235777
Drug: PDS01ADC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT
Trial: NCT04235777
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT
Trial: NCT00334139
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: every 4 weeks for 4 months
Trial: NCT01514630
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five grams of creatine monohydrate will be administered for eight weeks.
Trial: NCT01591668
Drug: Single Ascending Dose Cohorts GS-9620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Trial: NCT01049984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet daily for 18 weeks
Trial: NCT01974440
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
Trial: NCT01974440
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
Trial: NCT02753764
Drug: AZD7624
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02753764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01974440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
Trial: NCT00254553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tubes of placebo per day
Trial: NCT02712957
Drug: NEO6860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRPV1 antagonist
Trial: NCT01207752
Drug: Optive Lubricant Eye Drops
RxNorm normalized name: Refresh Optive Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tear eye drop
Trial: NCT02712957
Drug: NEO6860 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive substance
Trial: NCT02712957
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAID
Trial: NCT03084939
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Trial: NCT02712957
Drug: Naproxen placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive substance
Trial: NCT00162552
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with severe cirrhosis treated with a placebo
Trial: NCT02414555
Drug: vasopressor
RxNorm normalized name: Vasopressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
Trial: NCT01016145
Drug: Antipsychotics
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
Trial: NCT01016145
Drug: Antipsychotics
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
Trial: NCT00629551
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, capsules
Trial: NCT04677933
Drug: B: OLP-1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 patients will receive 10 µg OLP-1002 BIW OLP-1002
Trial: NCT04677933
Drug: C: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 patients will receive Placebo BIW
Trial: NCT02476058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
Trial: NCT03756922
Drug: FDL176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFTR potentiator
Trial: NCT03693391
Drug: Fluorine-18 Labeled [18F]-JNJ-64511070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
Trial: NCT01355822
Drug: PETN
RxNorm normalized name: PETN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaerythrithyltetranitrate: 80 mg orally twice a day
Trial: NCT01355822
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, twice daily
Trial: NCT01476124
Drug: GEn Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil placebo
Trial: NCT01381458
Drug: FSC
RxNorm normalized name: Dofscort 3%-1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone propionate / salmeterol xinofoate combination
Trial: NCT01899066
Drug: Lucentis, chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
Trial: NCT03175198
Drug: Prazaxa® Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
Trial: NCT01899066
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
Trial: NCT01344499
Drug: Ringer Lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: instillation of 1 liter of fluid at the end of laparoscopy
Trial: NCT00634920
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
Trial: NCT00634920
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
Trial: NCT02101268
Drug: Best Available Therapy (BAT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
Trial: NCT04358068
Drug: Azithromycin (Azithro)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT04358068
Drug: Placebo for Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02625753
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
Trial: NCT02625753
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
Trial: NCT01193218
Drug: Placebo (low dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once a day
Trial: NCT01193218
Drug: Placebo (mid dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once a day
Trial: NCT01193218
Drug: Placebo (high dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once a day
Trial: NCT03681028
Drug: Individualized therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose.
Trial: NCT02094794
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00239681
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT01712295
Drug: Salicylates
RxNorm normalized name: salicylates
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02641028
Drug: CERC-501
RxNorm normalized name: CERCIS SILIQUASTRUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERC-501
Trial: NCT02641028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03975296
Drug: patient controlled intravenous analgesia(PCIA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
Trial: NCT01677949
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion
Trial: NCT02446600
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02046447
Drug: Primary Cervical Dystonia (Trihexyphenidyl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
Trial: NCT04591535
Drug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Trial: NCT02790073
Drug: SNF472
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNF472 for calciphylaxis
Trial: NCT01108042
Drug: Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
Trial: NCT03569475
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine oral capsules
Trial: NCT03569475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral capsules
Trial: NCT04256317
Drug: ASTX030 (cedazuridine + azacitidine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC Capsules for oral administration.
Trial: NCT00660335
Drug: RG1068 (synthetic human secretin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose, IV infusion
Trial: NCT03621982
Drug: ADCT-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01342887
Drug: pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01028521
Drug: CM3.1-AC100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for sc injection, single ascending doses
Trial: NCT01028521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for sc injection
Trial: NCT03434613
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5mg 1T daily for 6 months
Trial: NCT03434613
Drug: Rosuvastatin/ezetimibe combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
Trial: NCT00108121
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no